MAM
NBSE

Martingale Asset Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Martingale Asset Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,131
Closed -$324K – 1070
2020
Q3 		$324K Buy
+2,131
New +$348K ﹤0.01% 896

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Martingale Asset Management's NBSE Position: Q4 2020 in Review

Martingale Asset Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2020, closing a stake of 2,131 shares — an estimated $324K sold.

Martingale Asset Management first reported a position in NBSE in Q3 2020 and held it in 1 quarter. The position peaked at $324K in Q3 2020. 53 funds tracked by Wall St. Rank hold NBSE as of Q4 2020.

  • Martingale Asset Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Martingale Asset Management sold 2,131 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $324K.
  • Martingale Asset Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Martingale Asset Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $324K in Q3 2020.
  • 53 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Martingale Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.